On September 15, 2023, NeuroBo Pharmaceuticals achieved a significant milestone by administering the initial dose of its experimental drug, DA-1241, ...
On September 8, 2023, Cantor Fitzgerald initiated coverage of Atossa Therapeutics Inc (NASDAQ:ATOS) with an optimistic outlook, giving it an ...
On September 8, 2023, Cantor Fitzgerald analyst Louise Chen shared her insights on Atossa Therapeutics (NASDAQ: ATOS), initiating coverage with ...
On August 17, 2023, analysts from StockNews.com released a research report that initiated coverage on shares of Atossa Therapeutics (NASDAQ:ATOS) ...
On August 17, 2023, analysts from StockNews.com released a research report that initiated coverage on shares of Atossa Therapeutics (NASDAQ:ATOS) ...
On August 14, 2023, Atossa Therapeutics (NASDAQ: ATOS) unveiled its financial results for the six months ending June 30, 2023. ...
On July 20, 2023, Atossa Therapeutics, a biopharmaceutical company in the clinical stage, received the green light from Health Canada ...
As of July 11, 2023, Atossa Therapeutics stands as a trailblazing biopharmaceutical company engaged in the development of groundbreaking medications ...
As of July 10, 2023, a total of 170 patients have been enrolled by Atossa Therapeutics for their Phase 2 ...
In a recent enigmatic turn of events, investment analysts at the prestigious StockNews.com have made an intriguing upgrade to the ...